VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

GU Cancers 2022 | Future of PARP inhibitors for urothelial carcinoma

Massimo Di Maio, PhD, University of Turin, Turin, Italy, discusses what we have learnt from the results from the URO-12 study about the use of PARP inhibitors as maintenance therapy for patients with advanced urothelial carcinoma. Prof. Di Maio also discusses the ATLANTIS trial, and how selection of patients for PARP inhibitor maintenance therapy based on molecular profiling could result in better outcomes. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.


Massimo Di Maio reports personal fees from AstraZeneca, Pfizer, Novartis, Roche, Takeda, Janssen, Eisai, Astellas, Merck Sharp & Dohme, Boehringer Ingelheim, research grant from Tesaro – GlaxoSmithKline.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter